Reviewing Entera Bio Ltd. (ENTX)’s and Agios Pharmaceuticals Inc. (NASDAQ:AGIO)’s results

Entera Bio Ltd. (NASDAQ:ENTX) and Agios Pharmaceuticals Inc. (NASDAQ:AGIO) compete against each other in the Biotechnology sector. We will compare them and contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Entera Bio Ltd. N/A 85.72 10.30M -1.01 0.00
Agios Pharmaceuticals Inc. 115.85M 24.35 348.28M -5.99 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Entera Bio Ltd. and Agios Pharmaceuticals Inc.

Profitability

Table 2 provides us Entera Bio Ltd. and Agios Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Entera Bio Ltd. 0.00% 0% 0%
Agios Pharmaceuticals Inc. -300.63% -48.2% -38.6%

Liquidity

The Current Ratio of Entera Bio Ltd. is 7 while its Quick Ratio stands at 7. The Current Ratio of rival Agios Pharmaceuticals Inc. is 6.9 and its Quick Ratio is has 6.9. Entera Bio Ltd. is better equipped to clear short and long-term obligations than Agios Pharmaceuticals Inc.

Analyst Recommendations

In next table is given Entera Bio Ltd. and Agios Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Entera Bio Ltd. 0 0 0 0.00
Agios Pharmaceuticals Inc. 0 0 2 3.00

On the other hand, Agios Pharmaceuticals Inc.’s potential upside is 56.09% and its consensus target price is $75.

Insider and Institutional Ownership

Entera Bio Ltd. and Agios Pharmaceuticals Inc. has shares held by institutional investors as follows: 14.7% and 0%. About 46.55% of Entera Bio Ltd.’s share are held by insiders. Insiders Comparatively, held 0.3% of Agios Pharmaceuticals Inc. shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Entera Bio Ltd. -0.47% -4.02% -3.56% -28.27% 0% 32.16%
Agios Pharmaceuticals Inc. -8.33% -20.89% -12.36% -31.47% -45.54% 2.69%

For the past year Entera Bio Ltd.’s stock price has bigger growth than Agios Pharmaceuticals Inc.

Summary

On 8 of the 10 factors Entera Bio Ltd. beats Agios Pharmaceuticals Inc.

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union bone fractures; and other platform modules. The company was founded in 2010 and is headquartered in Jerusalem, Israel.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. The company is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients. In addition, it is developing AG-881, a pan-IDH mutant inhibitor that is in Phase 1 clinical trials for the treatment of hematologic malignancies and solid tumors; and AG-348, a small molecule potent activator that is in Phase 2 clinical trial for the treatment of pyruvate kinase deficiency. It has a collaboration and license agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology; and Celgene International II Sarl to develop and commercialize AG-881 products. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.